CardioDynamics Reports Third Quarter 2008 Results, Seventh Consecutive Quarterly Revenue Growth and 15% Year to Date Revenu...(r of 2008 and positive operating cash fl...)

Date:10/9/2008

r of 2008 and positive operating cash flow for our full 2009 fiscal year. We'll continue to make judicious investments that drive increased revenue growth and help establish ICG in the treatment guidelines for heart failure and hypertension in the coming years."

Conference Call Information

Michael K. Perry, Chief Executive Officer, and Steve P. Loomis, Chief Financial Officer, will host a summary of CardioDynamics' third quarter 2008 results in a conference call today, Thursday, October 9, 2008, at 4:30 p.m. (EDT). To access the conference call, dial 800-346-7359 (Code 7784). International participants can call 973-528-0008 (Code 7784). A replay of the call will be available for one month following the call at 800-332-6854 (Code 7784). The international replay number is 973-528-0005 (Code 7784). The Internet webcast can be accessed through the Investor Relations section of the Company's website at http://www.cdic.com or at http://tinyurl.com/4dknlk.

About CardioDynamics

CardioDynamics International Corporation (Nasdaq: CDIC), the ICG Company, is the innovator and leader of an important medical technology called impedance cardiography (ICG). The Company develops, manufactures and markets noninvasive ICG products and ICG electrodes. The Company's ICG Systems are being used by physicians around the world to help battle the number one killer of men and women--cardiovascular disease. Partners include GE Healthcare, Philips Medical Systems and Mindray. For additional information, please refer to the Company's Web site at http://www.cdic.com.

Forward-Looking (Safe Harbor
'/>"/>

SOURCE CardioDynamics Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. CardioDynamics BioZ(R) ICG Technology Integrates with General Electric Healthcares Centricity(R) Electronic Medical Record (EMR) System
2. CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Companys Common Stock and Trading in Post-split Shares Begins May 9, 2008
3. CardioDynamics Receives Nasdaq Letter of Non-Compliance With Minimum Bid Price Requirement
4. CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series
5. CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego
6. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
7. CardioDynamics Provides 2007 Shareholder Meeting Update
8. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
9. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. Corgenix Reports Fiscal 2008 Financial Results